FindTrial
Sign In

A Study on Time Intervals Between Last Dose of Antagonist Administration & Trigger

A Randomized Controlled Trial Between Two Time Intervals of Last Dose of Antagonist Administration & Trigger-Does It Make a Difference? - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056365
Enrollment
100
Registered
2023-08-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z314- Encounter for procreative investigation and testing

Interventions

Intervention1: 1) Antagonist - Gonadotropin releasing hormone antagonist (GnRHa), recombinant human follicle stimulating hormone (rhFSH) and HP-Human menopausal Gonadotropin (HMG) 2) Dual Trigger - r

Sponsors

Dr. Aishwarya Parthasarathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 25 to 38 years. BMI in range of 18-35. GnRH antagonist protocol. Normal hormonal profile as assessed by DAY 2 FSH, TSH, Prolactin, and AMH. Written consent to participate in trial.

Exclusion criteria

Exclusion criteria: Hypogonadotropic hypogonadism. Premature ovarian insufficiency. Age more than 38 years. Patients not willing to participate in the trial.

Design outcomes

Primary

MeasureTime frame
To measure & compare oocyte recovery rate, M II rates, Fertilization & Blastocyst rate Timepoint: Baseline—

Secondary

MeasureTime frame
To measure posterior trigger LH, progesterone concentrations, clinical pregnancy rates, miscarriage rates & ongoing pregnancy ratesTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Aishwarya Parthasarathy

A4 Hospital and Maternity Centre

seventhsensed@gmail.com9094034016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026